【drug-news】氯吡格雷潜在的市场竞争者：阿斯利康的Brilinta
这个帖子发布于 16 年零 70 天前，其中的信息可能已发生改变或有所发展。
Another Potential Plavix Competitor: AstraZeneca’s Brilinta
It looks like another competitor is emerging for Plavix, the blood thinner that’s the second-biggest selling drug in the world.
AstraZeneca said today that its experimental drug Brilinta (generic name ticagrelor) did a better job than Plavix of reducing the risks of strokes and heart attacks in patients with acute coronary syndrome.
It’s too soon to say exactly what the results mean — the company hasn’t released the data, which are likely to be presented at a conference later this year and submitted for publication in a peer-reviewed journal.
But it’s clear that Plavix, co-marketed by Bristol-Myers Squibb and Sanofi-Aventis, is likely to come under increased competitive pressure. Generic copies of Plavix have already come on the market in Europe and are expected to go on sale in the U.S. in 2011, the WSJ reports.
Another Plavix competitor, Efient (generic name prasugrel; co-marketed by Eli Lilly and Daiichi Sankyo), has been approved in Europe and was recently recommended for U.S. approval by a panel of FDA advisers.
The Brilinta study whose results AstraZeneca reported today included more than 18,000 patients, and compared how Brilinta and Plavix reduced the risk of a composite of heart attacks, strokes and death from cardiovascular causes. Here’s a description of the study on a federal drug trials registry.
It will be interesting to see the complete, peer-reviewed data from the study to get a better sense of how Brilinta stacks up against Plavix. Getting a clearer look at efficacy will be important, as will learning more about safety risks — often a key issue with blood thinners, which can raise the risk of bleeding.
http://blogs.wsj.com/health/2009/05/11/another-potential-plavix-competitor-astrazenecas-brilinta/
It looks like another competitor is emerging for Plavix, the blood thinner that’s the second-biggest selling drug in the world.
AstraZeneca said today that its experimental drug Brilinta (generic name ticagrelor) did a better job than Plavix of reducing the risks of strokes and heart attacks in patients with acute coronary syndrome.
It’s too soon to say exactly what the results mean — the company hasn’t released the data, which are likely to be presented at a conference later this year and submitted for publication in a peer-reviewed journal.
But it’s clear that Plavix, co-marketed by Bristol-Myers Squibb and Sanofi-Aventis, is likely to come under increased competitive pressure. Generic copies of Plavix have already come on the market in Europe and are expected to go on sale in the U.S. in 2011, the WSJ reports.
Another Plavix competitor, Efient (generic name prasugrel; co-marketed by Eli Lilly and Daiichi Sankyo), has been approved in Europe and was recently recommended for U.S. approval by a panel of FDA advisers.
The Brilinta study whose results AstraZeneca reported today included more than 18,000 patients, and compared how Brilinta and Plavix reduced the risk of a composite of heart attacks, strokes and death from cardiovascular causes. Here’s a description of the study on a federal drug trials registry.
It will be interesting to see the complete, peer-reviewed data from the study to get a better sense of how Brilinta stacks up against Plavix. Getting a clearer look at efficacy will be important, as will learning more about safety risks — often a key issue with blood thinners, which can raise the risk of bleeding.
http://blogs.wsj.com/health/2009/05/11/another-potential-plavix-competitor-astrazenecas-brilinta/
3 2 1
